View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
March 29, 2011

Chembio Develops Assays for Rapid Disease Diagnosis

Chembio has developed a testing approach known as Dual Path Platform technology, which can help in the rapid diagnosis of HIV, influenza A and B, and hepatitis B and C. The point-of-care assays require a blood sample or oral fluid sample and can diagnose the disease in 15 minutes.

By cms admin

Chembio has developed a testing approach known as Dual Path Platform technology, which can help in the rapid diagnosis of HIV, influenza A and B, and hepatitis B and C.

The point-of-care assays require a blood sample or oral fluid sample and can diagnose the disease in 15 minutes.

The assays are designed to significantly shorten the time to diagnosis and lessen the cost of testing.

Chembio Diagnostics CEO Lawrence Siebert said Dual Path Platform assays can incorporate a cassette with up to five test lines on it, each of which is capable of confirming the presence of a specific condition at the same time.

“If performed immediately before an organ donation, this test would deliver results within minutes and considerably lessen the chances of an infected organ being transplanted into a patient,” Siebert said.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Hospital Management